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Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative disease primarily affecting motor
neurons. We recently identified intermediate-length polyglutamine (polyQ) expansions (27–33 Qs) in ataxin 2
as a genetic risk factor for sporadic ALS in North American ALS patients. To extend these findings, we
assessed the ataxin 2 polyQ repeat length in 1294 European ALS patients and 679 matched healthy controls.
We observed a significant association between polyQ expansions and ALS (>30 Qs; P 5 6.2 3 1023). Thus,
intermediate-length ataxin 2 polyQ repeat expansions are associated with increased risk for ALS also in
the European cohort. The specific polyQ length cutoff, however, appears to vary between different popu-
lations, with longer repeat lengths showing a clear association. Our findings support the hypothesis that
ataxin 2 plays an important role in predisposing to ALS and that polyQ expansions in ataxin 2 are a significant
risk factor for the disease.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a devastating
adult-onset neurodegenerative disease caused primarily by
a loss of motor neurons in the motor cortex, brainstem
and spinal cord, leading to generalized paralysis and death
within 2–5 years of disease onset. The disease is mostly
sporadic but 10% of patients have a self-reported family
history of ALS (FALS). Since the familial and sporadic
forms of the disease are clinically indistinguishable, it is
hoped that identifying the genetic contributors to FALS
will provide insight into sporadic forms of the disease
as well.
The first gene associated with FALS was SOD1, which
encodes superoxide dismutase 1 (1). SOD1 mutations
account for 12–23% of FALS and 1–7% of sporadic ALS
(SALS) cases, for an overall incidence of 5% (2). For
many of the remaining cases, the RNA-binding protein
TDP-43 (TAR DNA-binding protein) has been found to
accumulate abnormally in ubiquitinated pathological lesions
of brain and spinal cord neurons (3) and pathogenic mutations
in the TDP-43 gene, TARDBP, have been identified in rare
familial and SALS patients (4). Following the identification
of TDP-43, mutations in a second gene encoding a related
RNA-binding protein, FUS/TLS, was linked to ALS (5,6),
underscoring a role for RNA-binding proteins and RNA-
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processing pathways as critical for ALS pathogenesis (7). In
addition to TDP-43 and FUS, mutations in additional genes,
including VAPB, OPTN and VCP, have also been linked to
ALS (8–10). As more genetic contributors to ALS are discov-
ered, they will aid our understanding of disease mechanisms
and will suggest novel avenues for therapeutic intervention.
Spinocerebellar ataxia type 2 (SCA2) is one of a hetero-
geneous group of 28 autosomal dominant hereditary ataxias
(11) and is caused by polyglutamine (polyQ) tract expansions
in ataxin 2 (12–15). These polyQ expansions are encoded at
the DNA level in the ataxin 2 gene (ATXN2) by trinucleotide
repeats of CAG. The ataxin 2 polyQ tract length, though vari-
able, is most frequently 22–23, with expansions of .34
causing SCA2 (12–15). Like other spinocerebellar ataxias,
the hallmark pathology in SCA2 is the atrophy and loss of
Purkinje neurons from the cerebellar cortex. This manifests
clinically as deficits in motor coordination that affect gaze,
speech, gait and balance (16). In SCA2, motor neurons are
also known to degenerate, as in ALS, although these features
typically occur later than the cerebellar degeneration.
However, in selected cases, the motor neuron features of
SCA2 are prominent enough to mimic an ALS presentation
(17,18), indicating the potential for clinicopathological
overlap between SCA2 and ALS.
Recently, using a combination of yeast and fly genetics, bio-
chemistry, cell biology and human genetics, we identified
intermediate-length polyQ repeat expansions in ataxin 2 as a
genetic risk factor for ALS (19,20). We analyzed 915 North
American ALS patients and 980 healthy control individuals
and found that ataxin 2 polyQ repeat tracts of 27–33 Qs
were significantly associated with increased risk for ALS (19).
To extend these findings, we sought to test whether ataxin 2
intermediate-length polyQ expansions increase risk of ALS in
additional patient populations. In the present study, we com-
pared the ataxin 2 polyQ lengths of ALS and healthy controls
from European populations.
RESULTS
We compared the ataxin 2 polyQ repeat length in genomic
DNA from 1294 ALS patients and 679 neurologically
normal controls (Fig. 1, Table 1). We found that 20 of 679
control individuals (2.9%) harbored an ataxin 2 intermediate-
length polyQ expansion (range 27–30) compared with 45 of
1294 ALS patients (3.5%, range 27–35). This difference
was not statistically significant. However, we observed that,
within the intermediate-length range of repeats (27–33Q),
longer repeats were more common in ALS patients than the
controls (Fig. 1). Out of 679 controls, no individuals harbored
a polyQ repeat .30, whereas 14 of 1294 ALS patients (1%)
had a polyQ repeat length .30 (range 31–35). This difference
was statistically significant (P ¼ 6.2 × 1023). Thus,
intermediate-length ataxin 2 polyQ repeat expansions are
associated with increased risk for ALS. The specific polyQ
length cutoff likely varies between different ethnic
populations, with longer repeat lengths showing a stronger
association.
Six of the 13 patients with an ataxin 2 polyQ .30 were
FALS cases and 7 were SALS cases, but unfortunately DNA
was not available from any relatives for comparison. Clini-
cally, none of the patients showed signs or symptoms, includ-
ing age of onset or disease duration, different from patients
with polyQ ,30. In particular, ataxia, dementia, or any atypi-
cal features have not been observed. Unfortunately, postmor-
tem tissue is not available from any of the 13 patients. The
longest ataxin 2 polyQ repeat length among the controls was
30Q, which was found in two cases; a 72-year-old male and
a 57-year old male control subject, both without signs of
ALS or ataxia.
DISCUSSION
We recently identified intermediate-length ataxin 2 polyQ
repeat expansions as a genetic risk factor for ALS (19). In
the present study, we have assessed the role of ataxin 2
polyQ expansions in European ALS patients. These findings
indicate a significant association of polyQ repeats of .30Q
with increased risk for ALS. In the previous analysis of
North American ALS patients and controls (19), we found
that repeat lengths 27–33Q were significantly associated
with ALS, whereas in this study of European ALS patients
and controls, only repeats .30Q were significantly different
between ALS cases and controls (P ¼ 6.2 × 1023).
It is likely that the specific cutoff for ataxin 2 polyQ repeat
length and risk for ALS will vary from population to popu-
lation, and future studies aimed at replicating these findings
in additional ALS patient and control populations will help
define the clinically relevant range further. However, it is
perhaps unsurprising that the association of polyQ expansions
Figure 1. Distribution of ataxin 2 polyQ repeat lengths in ALS patients and
healthy controls. Compared with controls, there was a greater number of
ALS cases with polyQ repeats .30 (Fisher’s exact test, P ¼ 6.2 × 1023).
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on ALS risk is more robust with longer polyQ lengths, given
the biology of polyQ disease proteins and the effects of
polyQ expansions on their properties: longer polyQ lengths
have a more severe effect in model organisms ranging from
yeast to fly and worm to mouse (22–26). Furthermore, our
findings also suggest the possibility that SCA2 and ALS
might lie on different ends of a clinical spectrum, with
intermediate-length repeat expansions presenting with more
prominent motor neuron degeneration, indicative of ALS,
and much longer polyQ expansions resulting in cerebellar
degeneration and ataxia. This would predict that some SCA2
patients might occasionally present with clinical symptoms
indicative of ALS (17,18) and vice versa—namely that ALS
patients would present with ataxia (27, see Clinical Anecdote
in Supplementary Information to 19).
In addition to ataxin 2, there are also emerging hints that
other ataxins and ataxin-interacting proteins could be involved
in ALS. Copy number variants (CNVs) in ataxin 1 (ATXN1)
and ataxin 3-like protein (ATXN3L) were identified in a geno-
mewide search for CNVs associated with ALS (28) and an
intronic SNP in ataxin-2-binding protein 1 (A2BP1) was ident-
ified in analysis of Dutch and Irish SALS cases (29,30). Since
ataxin 1 and ataxin 3 have both been shown to interact geneti-
cally with ataxin 2 in Drosophila (31,32) and A2BP1 was dis-
covered by virtue of its ability to physically interact with
ataxin 2 (33), a testable hypothesis is that intermediate-length
polyQ expansions in ataxin 2 disrupt, alter or enhance its
normal interactions with one or more of these proteins.
Apart from these ataxin genes, our initial studies identified
genetic and physical interactions between ataxin 2 and
TDP-43 (19), so it will be important to define further the func-
tional and/or pathological interaction between TDP-43 and
ataxin 2 and how intermediate-length polyQ repeats affect
this interaction.
In summary, we confirm an association between ataxin 2
polyQ repeat expansions and increased risk for ALS by ana-
lyzing a large population of European ALS patients and con-
trols. In contrast to our initial study for ALS patients and
controls from North America (19), where the statistically sig-
nificant cutoff is polyQ length ≥ 27Q, the cutoff for this popu-
lation was .30Q. Our studies support the hypothesis that
ataxin 2 contributes to ALS. Future studies will be aimed
at defining the mechanisms by which intermediate-length
ataxin 2 polyQ expansions contribute to ALS pathogenesis.
MATERIALS AND METHODS
ALS patients and control samples
With written informed consent, blood samples were obtained
from 400 patients diagnosed with FALS [Sweden (184
patients), Germany (57), Switzerland (49), Finland (37),
Norway (20), Denmark (28), Portugal (23) and Iceland (2)]
and 894 patients diagnosed with SALS [Sweden (658),
Switzerland (236); 389 females and 505 males]. The mean
age of onset was 56.7 years for the FALS cases and 59.9
years for the SALS cases. All patients were diagnosed accord-
ing to standard criteria at specialized ALS clinics in Europe
(21). The patient cohort was compared with 679 controls
matched for age and gender. These were either spouses of
patients or healthy blood donors. The study was approved by
the institutional ethical review boards in each country.
PolyQ repeat size determination in ALS patients
and controls
We amplified ataxin 2 CAG repeats from individual samples
by polymerase chain reaction (PCR). PCR primers used for
amplification were designed to amplify the CAG repeat
region of human Ataxin-2 (bp 442–598). The 5′ primer was
SCA2-A6FAMnew: 5′-CCC CGC CCG GCG TGC GAG
CCG GTG TAT G-3′ (modified with the 6FAM fluorophor
into PCR). The 3′ primer was SCA2-B: 5′-CGG GCT TGC
GGA CAT TGG-3′. PCR cycles were as follows: 2 min at
948C, 35 cycles (1 min at 948C, 1 min at 608C, 1 min at
728C), and 5 min at 728C. PCR products were mixed with
Liz-500 size standard (Applied Biosystems) and were pro-
cessed for size determination on an ABI3730 sequencer. The
size of the repeats was determined with GeneMapperTM 4.0
software (Applied Biosystems).
Statistical analysis
Two-tailed Fisher’s exact tests were used to evaluate genetic
association between intermediate-length Ataxin-2 repeats
and ALS.
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